Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alterity TherapeuticsASX:ATH -2.88%33 3-Year Book Growth Rate is -32.00% as of Mar. 2026. GuruFocus rates ASX:ATH with a GF Score™ of 33/100. Among 1,129 Biotechnology companies, Alterity Therapeutics ranks worse than 73.78% on this metric.
During the past 12 months, Alterity Therapeutics's average Book Value per Share Growth Rate was 308.20% per year.
During the past 3 years, the average Book Value per Share Growth Rate was -32.00% per year.
During the past 5 years, the average Book Value per Share Growth Rate was -19.50% per year.
During the past 10 years, the average Book Value per Share Growth Rate was -25.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Alterity Therapeutics was 57.20% per year. The lowest was -51.80% per year. And the median was -19.80% per year.
Alterity Therapeutics (ASX:ATH) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Alterity Therapeutics 3-Year Book Growth Rate Related Terms
ASX:ATH vs VRTX, REGN, MRNA: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Alterity Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alterity Therapeutics 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Alterity Therapeutics's 3-Year Book Growth Rate falls into.
Alterity Therapeutics 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of -32.00% mean?
Alterity Therapeutics (ASX:ATH) has a 3-Year Book Growth Rate of -32.00% as of Mar. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Alterity Therapeutics and its competitors. According to the industry distribution chart, Alterity Therapeutics ranks #833 out of 1129 companies in the Biotechnology industry, placing it in the top 73.8%.
Is Alterity Therapeutics' 3-Year Book Growth Rate too high?
Alterity Therapeutics' current 3-Year Book Growth Rate is -32.00%. Based on the distribution chart, Alterity Therapeutics ranks #833 out of 1129 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alterity Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' 3-Year Book Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alterity Therapeutics ranks #833 out of 1129 companies for 3-Year Book Growth Rate. This places Alterity Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Alterity Therapeutics and its competitors. Alterity Therapeutics's current 3-Year Book Growth Rate is -32.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (ASX:ATH) has a current 3-Year Book Growth Rate of -32.00%. The current 3-Year Book Growth Rate is -32.00%. Alterity Therapeutics' overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Alterity Therapeutics (ASX:ATH), the current 3-Year Book Growth Rate is -32.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
33GF Score
Get the complete analysis for ASX:ATH
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ATH has been successfully added to your 
